NCT03493282View on ClinicalTrials.gov

Effect of CT1812 Treatment on Brain Synaptic Density

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

October 16, 2020

Study Completion Date

October 16, 2020

Conditions
Alzheimer Disease
Interventions
DRUG

Active Treatment- CT1812 100 mg

CT1812

DRUG

Active Treatment- CT1812 300 mg

CT1812

DRUG

Placebo

Matching Placebo

Trial Locations (1)

06510

Yale University School of Medicine, New Haven

Sponsors
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Cognition Therapeutics

INDUSTRY

NCT03493282 - Effect of CT1812 Treatment on Brain Synaptic Density | Biotech Hunter | Biotech Hunter